{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:32:23Z","timestamp":1783704743671,"version":"3.55.0"},"reference-count":38,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate the long\u2010term efficacy and safety data at 104\u2009weeks in tirzepatide\u2010treated participants with type 2 diabetes who had inadequate glycaemic control on metformin and\/or sulfonylurea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This post\u2010hoc analysis was based on the SURPASS\u20104 data (NCT03730662), a multicenter, Phase III trial. Participants were randomised to receive tirzepatide (5, 10, or 15\u2009mg) or insulin glargine. The primary efficacy endpoint was change in HbA1c levels from baseline to 104\u2009weeks. Key secondary endpoints were changes in body weight and the proportion of participants achieving HbA1c &lt;7.0%. Safety endpoints included the incidence of treatment\u2010emergent adverse events (AEs) and hypoglycaemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This post\u2010hoc analysis included 1,500 participants. At Week 104, participants in the tirzepatide groups had significantly greater mean reduction in HbA1c (5\u2009mg: \u22122.3%, 10\u2009mg: \u22122.5%, 15\u2009mg: \u22122.6%) compared with the insulin glargine group (\u22121.0%) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Participants in the tirzepatide groups had significantly greater reduction in body weight (5\u2009mg: \u22127.6\u2009kg, 10\u2009mg: \u221210.0\u2009kg, 15\u2009mg: \u221211.4\u2009kg) compared with the insulin glargine group (2.1\u2009kg) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Significantly more participants in the tirzepatide group achieved HbA1c &lt;7.0% compared with the insulin glargine group (p\u2009&lt;\u20090.001). The incidence of hypoglycaemia was lower in the tirzepatide groups, and gastrointestinal AEs were mild or moderate in severity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tirzepatide significantly improved glycaemic control and body weight reduction compared to insulin glargine over 104\u2009weeks in participants with type 2 diabetes inadequately controlled on metformin and\/or sulfonylurea. The safety profile of tirzepatide was acceptable, with a lower incidence of hypoglycaemia than insulin glargine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70047","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T05:00:17Z","timestamp":1757480417000},"page":"6480-6490","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long\u2010term efficacy and safety of tirzepatide in participants with type 2 diabetes with inadequate glycaemic control on metformin and\/or sulfonylurea: Post\u2010hoc analysis of\n                    <scp>SURPASS<\/scp>\n                    \u20104"],"prefix":"10.1111","volume":"27","author":[{"given":"Haixia","family":"Guan","sequence":"first","affiliation":[{"name":"Department of Endocrinology Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University  Guangzhou People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Jiang","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism Center The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology  Luoyang People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolic Diseases Henan Provincial People's Hospital  Zhengzhou People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5321-6827","authenticated-orcid":false,"given":"Jie","family":"Sun","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Xu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1305-1598","authenticated-orcid":false,"given":"Linong","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Peking University People's Hospital  Beijing People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci22\u20100034"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25\u2010SINT"},{"key":"e_1_2_10_4_1","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2021"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/cd24\u2010aint"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26180"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.S141235"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/cd22\u20100029"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhe.2023.10.015"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300\u2010021\u201000997\u20100"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.S313837"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300\u2010015\u20100114\u20102"},{"key":"e_1_2_10_13_1","unstructured":"FDA approves Lilly's Mounjaro\u2122 (tirzepatide) injection the first and only GIP and GLP\u20101 receptor agonist for the treatment of adults with type 2 diabetes.2022."},{"key":"e_1_2_10_14_1","unstructured":"FDA.FDA approves new medication for chronic weight management.2023. Accessed February 5 2025.https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-medication-chronic-weight-management"},{"key":"e_1_2_10_15_1","unstructured":"European Medicines Agency (EMA).Mounjaro.2024. Accessed February 5 2025.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mounjaro#authorisation-details"},{"key":"e_1_2_10_16_1","unstructured":"Eli Lilly's diabetes drug tirzepatide gets approval in China.The Business Times.2024. Accessed February 5 2025.https:\/\/www.businesstimes.com.sg\/companies\u2010markets\/consumer\u2010healthcare\/eli\u2010lillys\u2010diabetes\u2010drug\u2010tirzepatide\u2010gets\u2010approval\u2010china"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13098\u2010023\u201001198\u20104"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/db23\u2010777\u2010P"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14943"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010023\u201002344\u20101"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(21)01443\u20104"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(21)02188\u20107"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14056"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k2693"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25\u2010S009"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc24\u2010S006"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12071681"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110691"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10238\u2010007\u20100121\u20103"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2213\u20108587(22)00070\u20105"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.31128\/AJGP-03-21-5866"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.78357"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2023.09.007"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2018.09.009"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118695432"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118924853.ch35"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15\u20100279"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569\u2010023\u201000877\u2010z"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618\u2010024\u201002441\u2010z"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70047","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/full-xml\/10.1111\/dom.70047","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T06:23:08Z","timestamp":1771309388000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.70047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/dom.70047"],"URL":"https:\/\/doi.org\/10.1111\/dom.70047","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.70047\/v3\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v1\/review8","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v3\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v1\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v1\/review6","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v2\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v2\/review6","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v3\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v1\/review7","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v3\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v1\/review9","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v1\/review5","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v2\/review5","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v2\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70047\/v2\/review7","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"assertion":[{"value":"2025-02-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}